To access this element change to forms mode OFF
Grant Award View - GA279501
Development of novel GPR52 agonists for the treatment of schizophrenia
GA ID:
GA279501
Agency:
National Health and Medical Research Council (NHMRC)
Approval Date:
7-Dec-2022
Publish Date:
23-Jan-2023
Category:
Medical Research
Grant Term:
1-Jan-2023 to 31-Dec-2024
Value (AUD):
$793,214.28
(GST inclusive where applicable)
One-off/Ad hoc:
No
Aggregate Grant Award:
No
PBS Program Name:
NHMRC 21/22 1.1 Health and Medical Research
Grant Program:
Development Grants
Grant Activity:
Development of novel GPR52 agonists for the treatment of schizophrenia
Purpose:
We are developing a novel class of drug candidates as better treatments for schizophrenia, a debilitating psychiatric disorder. Current therapeutics address only one component of the disorder and cause significant side-effects, often leading to discontinuation of treatment. There is a well-recognized and significant unmet need for novel, effective treatment options with fewer side effects that also address the negative symptoms and cognitive impairments core to schizophrenia.
GO ID:
GO Title:
NHMRC Development Grants 2022 for funding in 2023
Internal Reference ID:
2022/GNT2022585
Selection Process:
Targeted or Restricted Competitive
Confidentiality - Contract:
Yes
Confidentiality Reason(s) - Contract:
Privacy Act 1988
Intellectual property
Intellectual property
Confidentiality - Outputs:
Yes
Confidentiality Reason(s) - Outputs:
Intellectual property
Grant Recipient Details
Recipient Name:
Monash University
Recipient ABN:
12 377 614 012
Grant Recipient Location
Suburb:
Clayton
Town/City:
Clayton
Postcode:
3800
State/Territory:
VIC
Country:
AUSTRALIA
Grant Delivery Location
State/Territory:
VIC
Postcode:
Country:
AUSTRALIA